In contrast, adjudicated signals have not emerged from randomized trials or their open-label extensions, which reduces the prior probability that PCSK9 inhibition causes clinically meaningful neuropathy in the general cardiovascular population, though very infrequent idiosyncratic events cannot be excluded. Here, PCSK9 is linked to neuropathy.